Opendata, web and dolomites

IPUD SIGNED

An Implantable Peritoneal Ultrafiltration Device that actively and continuously prevents fluid overload in congestive heart failure patients

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 IPUD project word cloud

Explore the words cloud of the IPUD project. It provides you a very rough idea of what is the project "IPUD" about.

million    hemodynamic    moderate    preventing    severe    resistant    fluids    slowly    treatment    eliminating    invasive    instability    chf    worldwide    fluid    extracellular    monitoring    preclinical    prevent    device    safety    implantable    healthcare    removal    congestion    laparoscopic    ultrafiltration    treatments    24    pathologic    recurrence    systemic    diuretic    physicians    worsening    continuous    validate    recurred    life    heart    acute    perform    water    verification    absorbs    minimally    eliminates    frequent    isotonic    billion    arrhythmia    thanks    quality    efficacy    platform    chronic    26    infusion    health    clinical    body    significantly    paragate    shock    function    solutions    carry    renal    pump    validation    accumulation    congestive    metabolic    sensing    guarantees    complications    drains    trial    overload    medical    patient    intravenous    catheter    aggressive    pilot    reduce    diuresis    peritoneal    accumulates    direct    urinary    hospitalizations    dialysis    therapy    volume    patients    people    global    ipud   

Project "IPUD" data sheet

The following table provides information about the project.

Coordinator
PARAGATE MEDICAL LTD 

Organization address
address: 13 WADI EL HADJ
city: NAZARETH
postcode: n.a.
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Israel [IL]
 Total cost 2˙909˙785 €
 EC max contribution 2˙036˙849 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2019
 Duration (year-month-day) from 2019-08-01   to  2021-07-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    PARAGATE MEDICAL LTD IL (NAZARETH) coordinator 2˙036˙849.00

Map

 Project objective

Pathologic fluid overload (congestion) is a medical condition when high volume of fluid (water) accumulates in the body leading to congestive heart failure (CHF). CHF is a severe global health problem affecting each year ~26 million people worldwide, of which 8 million are chronic and diuretic resistant patients. Current solutions for fluid overload in diuretic resistant patients such as infusion pump for intravenous (IV) diuresis, catheter-based device for ultrafiltration therapy and peritoneal dialysis all carry complications and are acute treatments which do not prevent recurrence. Paragate developed IPUD a unique implantable peritoneal ultrafiltration system for continuous monitoring and removal of extracellular fluids in CHF patients. It is minimally invasive (laparoscopic approach) and continuously (24/7) and slowly absorbs systemic isotonic extracellular fluid and drains it to the urinary system preventing recurred accumulation. In addition, IPUD guarantees a continuous monitoring of the fluid as well as the urinary system function thanks to a sensing system (embedded into the implantable system) and a treatment management platform. In this way, physicians have a direct control of the treatment and patient’s condition. The controlled, moderate non-aggressive fluid removal eliminates the main complications associated with the acute and aggressive treatments that lead to hemodynamic shock, worsening of renal function, arrhythmia and metabolic instability. Thanks to IPUD, patients will improve their quality of life eliminating frequent hospitalizations with a more effective treatment and healthcare systems will significantly reduce the €100 billion/year cost for frequent hospitalizations and treatment costs. The Phase 2 project will enable Paragate to scale-up production, perform validation and verification activities including a preclinical study; and validate the safety and efficacy of IPUD in a pilot clinical trial.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "IPUD" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "IPUD" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

COPI (2020)

Carbon Offset Plug-in

Read More  

Magnesys (2019)

Efficient filtering of metallic impurities in food processing

Read More  

LIVELMIA (2019)

Innovative assay for microRNAs analysis

Read More